SCHEMBL2177698

SCHEMBL2177698

COc1ccc(NC(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N(C(C(=O)O)C(C)C)C4)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
TP53 P04637 2/20 0.60
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CSGALNACT1 Q8TDX6 1/20 0.42
SDCBP O00560 4/20 0.42
SDC2 P34741 4/20 0.42
MAPT P10636 1/20 0.42
GAA P10253 1/20 0.41
ATM Q13315 1/20 0.41
KDR P35968 1/20 0.41
DGAT1 O75907 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177691 1.00 LMNA (0.60) LMNATP53RAB9ANPC1POLB
SCHEMBL2179308 0.92 LMNA (0.58) LMNATP53SMN1; SMN2MEN1KMT2A
SCHEMBL2177961 0.92 LMNA (0.58) LMNATP53SMN1; SMN2MEN1KMT2A
SCHEMBL2180785 0.92 LMNA (0.60) LMNATP53RAB9ANPC1POLB
SCHEMBL2178532 0.92 LMNA (0.60) LMNATP53RAB9ANPC1POLB
SCHEMBL2181268 0.92 TP53 (0.60) LMNATP53RAB9ANPC1POLB
SCHEMBL2181262 0.92 TP53 (0.60) LMNATP53RAB9ANPC1POLB
SCHEMBL2178942 0.92 TP53 (0.53) LMNATP53RAB9ANPC1SMN1; SMN2
SCHEMBL2177471 0.92 TP53 (0.53) LMNATP53RAB9ANPC1SMN1; SMN2
SCHEMBL2180197 0.92 TP53 (0.57) LMNATP53RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885TP53 2093/4885RAB9A 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.